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Abstract
Purpose: Oral propranolol has become a promising treatment of capillary hemangiomas (CHs) despite concerns
of side effects associated with systemic beta-blockers. The objective of this study was to investigate the distribution of propranolol in periocular tissues and in plasma after topical application of propranolol as compared
with intravenous and oral administration of propranolol.
Methods: Each rabbit received propranolol as ophthalmic solution (1%) in one eye (1.5 mg dose), intravenous
injection (1.5 mg dose), or commercially available propranolol oral solution (5 mg dose). The periocular tissues
(e.g., eyelids and extraocular muscles) and blood were collected and assayed for propranolol.
Results: After topical instillation of 1.5 mg propranolol, high amounts of propranolol were rapidly delivered to
the eyelids and extraocular muscles (4 - 32 mg/g at 1 h after dosing). The drug in these tissues was slowly cleared,
and significant amounts of the drug ( > 0.4 mg/g) were still present at 24 h after the topical application. After oral
administration of a clinically relevant dose of 5 mg propranolol, the drug concentrations in the periocular tissues
were relatively low ( < 0.4 mg/g) at 1 h after dosing and generally undetectable at 8 h after dosing. After an
intravenous injection of 1.5 mg propranolol, the drug concentrations in the eyelids and extraocular muscles were
in the range of 0.2 - 1 mg/g at 1 h after dosing. The plasma concentration of the drug after the intravenous
injection was significantly higher than that after topical application of the same dose. The higher drug concentrations in the periocular tissues of the treated eyes as compared with untreated eyes suggest direct penetration of the drug into the periocular tissues from the administration site after topical application.
Conclusions: Topical administration can provide increased concentrations of propranolol in the periocular tissues and, thus, is superior to systemic administration for the treatment of periocular CH.

Introduction

C

apillary hemangiomas (CHs) are the most common
benign tumors in infants. The CHs can cause serious
morbidity and mortality depending on their size and location.1–3 About 7% of CHs involves the periocular regions
such as orbit and eyelids.4,5 If untreated or ineffectively
treated, complications such as astigmatism, ptosis, eyelid
closure, strabismus, amblyopia, and ultimately vision loss
may occur in patients with periocular CHs.6,7 The treatment
options for periocular CHs include topical, intralesional, or
systemic steroids, surgical excision, and a-interferon or vincristine. All these treatments have potential severe side effects and varying response rates to periocular CHs.8
Leaute-Labreze et al. first discovered that propranolol, a
non-selective adrenergic beta-blocker, can inhibit growth and

cause regression of segmental CHs in 2008.9 Many physicians have since become interested in treating CHs, including
periocular CHs, with oral propranolol. Oral propranolol was
found to be effective in the treatment of CHs,4,6,10–12 despite
potential side effects of systemic propranolol in infants.13,14
Systemic and chronic use of propranolol can cause bradycardia, hypotension, and hypoglycemia. Although oral propranolol has been suggested to be a promising therapy for
CHs, no data on the distribution of propranolol in periocular
tissues are available, which is important for the design of
dosing regimen and development of a more effective and
safer drug delivery method in treating periocular CHs.
It is hypothesized that topical drug administration is superior to systemic administration by delivering high concentrations of drugs directly to the target periocular tissues,
minimizing systemic exposure, and avoiding undesirable
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systemic effects. The objectives of this study were to (1) study
periocular tissue distribution of propranolol in a rabbit
model after a single topical ocular instillation and (2) compare these results with those after oral and intravenous administration. The findings in this study may help physicians
optimize the dosing regimen of current oral propranolol
treatment in periocular CHs and support the use of topical
propranolol as an alternative to oral propranolol for periocular CH therapy.

Methods
Materials
Propranolol hydrochloride (purity ‡ 98%) and timolol
maleate (purity ‡ 98%) were purchased from Sigma-Aldrich
(St. Louis, MO) and Spectrum Chemical MFG (Gardena,
CA), respectively. Propranolol solutions for topical and intravenous administration (0.5% and 1%) were prepared in
pH 7.4 phosphate-buffered saline (PBS). Oral propranolol
solution (40 mg in 5 mL) was purchased from Roxane Laboratories (Columbus, OH). Timolol maleate solution (11.7 mg/mL)
was prepared in PBS and used in high-performance liquid
chromatography (HPLC) assay. PBS (pH 7.4, consisting of
0.01 M phosphate buffer, 0.0027 M potassium chloride, and
0.137 M sodium chloride) was prepared by dissolving PBS
tablets (Sigma-Aldrich) in distilled, deionized water. Triethylamine and methanol (HPLC grade) were purchased from
Fisher Scientific (Fair Lawn, NJ). All materials were used as
received.

Animals
New Zealand white rabbits (male, 2 - 2.5 kg) were purchased from Myrtle Rabbitry (Thompsons Station, TN). All
experiments were conducted in adherence to the Association
for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and under the approval of the Institutional Animal
Care and Use Committee at the University of Cincinnati.

Topical administration
Three drops of 50 mL propranolol solutions (1%) were topically applied *30 s apart to the lower cul-de-sac of the
right eye of each rabbit with a calibrated pipette. The eyelids
were briefly closed to simulate blinking after each topical
instillation of propranolol. The contralateral eye was not
treated and served as an untreated control. At 1, 2, 4, 8, and
24 h postadministration, blood samples were collected, the
animals were euthanized with pentobarbital (200 mg/kg),
and periocular tissues were dissected from both treated and
untreated eyes. The blood samples were centrifuged at 3,400
g for 10 min to yield plasma samples. The periocular tissue
samples were immediately rinsed with PBS and patted dry
with Kimwipes. The plasma and the periocular tissue
samples were stored at - 20C until assay.
The periocular tissues analyzed in this study included
inner and outer layers of upper and lower eyelids, bulbar
conjunctiva, extraocular muscles (labeled superior, inferior,
lateral, and medial muscles), and periocular fat. The superior
muscles included the superior rectus and the superior oblique. The inferior muscles included the inferior rectus and
the inferior oblique. The lateral and medial muscles were the
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lateral and medial rectus that had been pooled from each eye
of the animal in the assay. The inner layers of the eyelids
mainly included the palpebral conjunctiva and tarsal plate.
The outer layers of the eyelids mainly included the skin and
orbicularis muscle.

Oral administration
Commercially available propranolol oral solution of
0.625 mL (5 mg propranolol) was orally administered to
rabbits by using a calibrated pipette. The dose was chosen to
be similar to the clinical dose given to infants (*2 mg/kg).
Blood samples were withdrawn at 1, 4, and 8 h after dosing,
and the rabbits were sacrificed immediately after blood
sampling. The periocular tissue and blood samples were
collected as described (see ‘‘Topical administration’’ section).

Intravenous administration
Propranolol solution (0.5%) of 0.3 mL (1.5 mg propranolol)
was intravenously administered into the marginal ear vein of
each rabbit. Blood samples were collected at 1 h after dosing,
and the rabbits were sacrificed with pentobarbital overdose.
The periocular tissue and blood samples were collected as
described (see ‘‘Topical administration’’ section).

Sample extraction
Propranolol was extracted from the plasma by using the
method of Dali et al. with minor modifications.15 Briefly,
10 mL of timolol maleate solution (11.7 mg/mL) and 100 mL of
0.25 M sodium hydroxide were added into 500 mL plasma
sample placed in a screw-capped glass tube and vortexed for
10 s. Timolol maleate was the internal standard in the HPLC
assay. Three milliliters of ethyl acetate were then added into
the tube, and the mixture was vortexed for 30 s. The organic
phase in the tube was separated by centrifugation at 3,400 g
for 10 min, removed from the tube, and dried under a stream
of air at 50C. After drying, the residue was reconstituted in
100 mL of the mobile phase used in the HPLC assay (see
‘‘Propranolol assay’’ section). The reconstituted sample was
vortexed for 10 s and centrifuged at 3,400 g for 5 min. An
aliquot of the supernatant (25 mL) was then removed for the
HPLC assay. The recovery of the extraction method was
tested by adding a known amount of propranolol in the
plasma and found to be 69% – 6% (n = 5).
The periocular tissues were cut into small pieces, incubated with 1 mL of methanol overnight at room temperature,
and then sonicated for 30 min. The mixtures were centrifuged at 2,200 g for 5 min, and 500 mL of supernatant were
removed. Ten microliters of timolol maleate solution
(11.7 mg/mL) was added to the supernatant. The supernatant
was then vortexed for 10 s and dried under a stream of air at
50C. After drying, the residue was reconstituted in 100 mL of
the HPLC mobile phase (see ‘‘Propranolol assay’’ section).
The reconstituted sample was vortexed for 10 s and centrifuged at 3,400 g for 5 min. An aliquot of the supernatant
(25 mL) was removed from the centrifuged sample and analyzed by HPLC. The recovery of the extraction method for
the periocular tissues was determined by adding a known
amount of propranolol to the periocular tissues. The recovery
was found to be 77% – 6%, 75% – 7%, 97% – 10%, 74% – 8%,
and 79% – 20% (n = 3) for the inner layers of eyelids, outer
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layers of eyelids, bulbar conjunctiva, extraocular muscles,
and periocular fat, respectively.

Propranolol assay
The HPLC system (Prominence, Shimadzu, Columbia,
MD) consisted of CBM-20A system controller, LC-20AT
solvent delivery module, SIL-20A autosampler, SPD-20A
UV-Vis detector, and a C18 column (Microsorb-MV,
4.6 mm · 150 mm; Varian, Inc., Lake Forest, CA). The HPLC
assay was performed at room temperature (20C – 2C). The
mobile phase consisted of 500 mL water, 500 mL methanol,
and 1.0 mL triethylamine, with its pH adjusted to pH 3.5
using acetic acid. The mobile phase was delivered at a flow
rate of 1.0 mL/min. The injection volume was 25 mL, and the
detection wavelength was 295 nm. Calibration curves were
constructed by using solutions of known concentrations of
propranolol in the mobile phase. The calibration curves were
found to be linear (r2 > 0.999) from 10 to 500 ng/mL for the
plasma samples and from 0.025 to 75 mg for the periocular
tissue samples.

Statistical analysis
In the topical application studies, the average propranolol
concentrations in the periocular tissues of treated and untreated eyes were calculated, respectively. The propranolol
concentrations of the periocular tissues from both eyes were
averaged in the systemic administration studies. All data are
presented as means and standard deviations (mean – SD)
with n values representing the number of replicates in each
set of data. Statistical differences were determined by using
Student’s t-tests and considered to be significant at a level of
P < 0.05.

Results
Ocular instillation
The concentrations of propranolol in the periocular tissues
of the treated eyes after topical instillation of 1% propranolol
ophthalmic solution at 1.5 mg dose are shown in Fig. 1. The
concentrations of propranolol reached their peaks at *1 - 2 h
after dosing in all periocular tissues studied. The highest
peak concentration was observed in the lower eyelid outer
layers (82 mg/g), followed by the upper eyelid outer layers
(12 mg/g), inferior muscles (11 mg/g), bulbar conjunctiva
(7.1 mg/g), lower eyelid inner layers (6.8 mg/g), upper eyelid
inner layers (4.8 mg/g), lateral and medial muscles (4.1 mg/g),
superior muscles (3.9 mg/g), and periocular fat (1.8 mg/g).
After reaching the peak concentrations, the drug concentrations in these tissues quickly decreased from 2 to 4 h postdosing and then slowly decreased through 24 h postdosing.
For example, the drug concentration in the inner layers of
lower eyelids decreased from the peak concentration at 1 h
postdosing to about 40% of the peak concentration at 2 h
postdosing and then to about 20% of the peak concentration
at 4 h postdosing. From 8 to 24 h postdosing, the decrease in
drug concentration in these tissues was marginal ( < 20%). In
general, the drug concentrations in these tissues (except the
periocular fat) were higher than 0.4 mg/g, and could be as
high as 11 mg/g, for example, in the lower eyelid outer layers,
at 24 h after dosing. Although relatively high amounts of
propranolol were delivered to the periocular tissues of ipsi-

FIG. 1. Concentrations of propranolol in the treated ipsilateral periocular tissues (a) eyelids (e.g., upper eyelid inner
layers, upper eyelid outer layers, lower eyelid inner layers,
and lower eyelid outer layers) and (b) extraocular muscles
(superior muscles, inferior muscles, and lateral and medial
muscles), bulbar conjunctiva, and periocular fat, after topical
instillation of 1.5 mg propranolol. Drug concentrations in
plasma after topical instillation are presented for comparison. Data represent the mean and standard deviation
(mean – SD, n = 3 - 4).
lateral eyes after topical application, significantly lower or
insignificant amounts of propranolol were detected in the
periocular tissues of the untreated contralateral eyes (e.g.,
< 0.4 mg/g at 1 h postdosing); the concentrations of propranolol in these tissues of the untreated eyes were 1 - 2
orders of magnitudes less than those of the treated eyes. The
drug concentrations in plasma were also significantly lower
than the drug concentrations in the periocular tissues of the
treated eyes at all time points studied (Fig. 1a). The plasma
concentration peaked at 1 h postdosing (27 – 3 ng/mL) and
decreased to 12 – 2 ng/mL at 24 h postdosing.

Systemic delivery
Figure 2 shows the propranolol concentrations in the
periocular tissues after oral administration of propranolol at
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FIG. 2. Concentrations of propranolol in the periocular tissues after oral
administration of a commercially
available propranolol oral solution
(Roxane) at a dose of 5 mg propranolol. The data represent the average
propranolol concentrations in both
eyes after administration (mean – SD,
n = 6). Missing bars indicate that the
drug was not detectable in the periocular tissues at 4 and/or 8 h after oral
administration. Propranolol was not
detectable in the bulbar conjunctiva.

5 mg dose. Peak concentrations of propranolol were observed at 1 h after dosing in all periocular tissues except
bulbar conjunctiva. The drug concentrations in these tissues
quickly decreased after reaching the peak concentrations and
were generally not detected at 8 h postdosing.
The drug concentrations in the periocular tissues at 1 h
after topical (1.5 mg), intravenous (1.5 mg), and oral (5 mg)
administration of propranolol are compared in Fig. 3. After
intravenous and oral administration, the drug concentrations in the periocular tissues (except the bulbar conjunctiva
and periocular fat) were in the range of 0.2–1.1 mg/g and
0.05–0.4 mg/g, respectively, which were *6–500-fold lower
as compared with those after topical application. The drug
was not detectable in the bulbar conjunctiva after oral
administration, and drug concentration in the bulbar con-

FIG. 3. Comparison of propranolol
concentrations in the periocular tissues
and plasma at 1 h after topical (1.5 mg
dose), intravenous (1.5 mg dose), and
oral (5 mg dose) administration of
propranolol. The data represent the
average propranolol concentrations in
the treated eye after topical application
and in both eyes after systemic administration (mean – SD, n = 3 - 8).
Missing bar indicates that the drug
was not detectable in the bulbar conjunctiva at 1 h after oral administration.

junctiva after intravenous injection was lower than that
after topical application. The periocular fat showed
the highest drug concentration among the periocular tissues studied (2.4 – 0.5 mg/g) after intravenous injection,
which was comparable to that after topical application
(1.8 – 0.9 mg/g) and higher than that after oral propranolol
(0.34 – 0.03 mg/g). The plasma concentration of propranolol at 1 h after intravenous injection of 1.5 mg of propranolol (45 – 11 ng/mL) was significantly higher (P < 0.05)
than the level observed after topical administration of
the same dose (27 – 3 ng/mL) or oral administration of
5 mg of propranolol (31 – 8 ng/mL). However, the plasma
concentrations after topical and oral administration of
propranolol at the respective doses were not significantly
different (P > 0.05).
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Discussion
Topical delivery
The CH is the most common periocular tumor in childhood that may involve the eyelids, the orbit, or both. They
can be small or extensive and superficial or deep.16 Superficial CHs are near the surface of the skin and have a bright
red appearance. Deep CHs generally grow in the deeper
layers of the skin and are manifested as compressible masses
in the periocular regions. Tumor growth in the eyelids, orbit,
and extraocular muscles can cause severe ocular complications such as strabismus, amblyopia, and vision loss.16,17
Particularly, when the visual development is affected due to
tumor growth in these periocular regions, patients need to be
treated immediately.18 Oral propranolol is more clinically
acceptable for periocular CHs than corticosteroid treatments
due to the well-known side effects of corticosteroid treatment
and effectiveness of propranolol therapy.19 Currently, propranolol is only administered systemically despite the potential side effects associated with systemic propranolol.
There is no generally accepted protocol for CH therapy using
oral propranolol, and the dosing regimen is usually based on
the clinical experience of physicians.
Topical application has been shown to be a preferred route
of administration for treating diseases affecting anterior tissues of the eye as compared with systemic delivery. The
feasibility and effectiveness of delivering therapeutic levels
of drugs to periocular tissues after topical application have
not been well established. The literature of drug delivery to
periocular tissues is very limited. As shown in Fig. 1, the results in the present study show that topical application can
deliver relatively high concentrations of propranolol (on the
order of micrograms per gram tissue) to the periocular tissues
including the eyelids and extraocular muscles. The peak concentrations of the drug in the periocular tissues studied occurred at *1 - 2 h after topical application, indicating that the
drug was rapidly taken up by the tissues from the administration site. Significant levels of propranolol ( > 0.4 mg/g) were
still detectable in the periocular tissues (except the periocular
fat) at 24 h postdosing, thus suggesting slow clearance of the
drug from these tissues. Propranolol preferentially distributed
into the outer layers of lower eyelid after topical instillation. It
was also observed that the drug concentrations were higher in
the lower eyelid tissues and inferior muscles than in the upper
eyelid tissues and superior muscles. This was likely related to
the instillation of the topical propranolol solution in the lower
cul-de-sac during drug administration. Together, the results in
this study demonstrate the feasibility and effectiveness of delivering significant amounts of propranolol to the periocular
tissues after topical instillation.
To study the penetration mechanisms after topical application, the propranolol concentrations in the untreated eyes
were compared with those in the treated eyes. The lower
drug concentrations detected in the untreated eyes as compared with those in the treated eyes suggest that the drug
penetrated directly into the periocular tissues from the administration site and that redistribution of the drug to the
tissues from systemic circulation was insignificant.

Systemic delivery
Clinically, propranolol is often orally administered at a
dose of 2 mg/kg/d in a divided dose. The pharmacologically
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optimal dosing interval for propranolol is every 6 h, but
patient compliance is improved if the medication is given
every 8–12 h.8,20,21 In the present study, a clinically relevant
oral dose of 5 mg (*2 mg/kg) was chosen but was administered in a single-dosing regimen to ensure measurable
propranolol concentrations in the periocular tissues. It was
found that propranolol was rapidly absorbed and distributed to the periocular tissues reaching their peak concentrations at 1 h after oral administration. The peak drug
concentrations ( < 0.4 mg/g) in the periocular tissues after
5 mg oral dose were significantly lower than those after
topical application at a lower dose of 1.5 mg propranolol.
After reaching the peak concentrations, drug concentrations
in the tissues quickly decreased and were not detectable in
all periocular tissues at 8 h postadministration in oral administration except in the outer layers of eyelids and the
periocular fat. This shows that oral administration at a clinical dose delivered only small amounts of propranolol into
these periocular tissues compared with topical application at
a lower dose.
It is known that propranolol is subjected to extensive firstpass metabolism after oral administration. In adults, only
about 25% of the dose reaches systemic circulation. In rare
cases, intravenous propranolol has been used to treat deep
and extensive periocular CHs.11 In the present study, the
same dose of propranolol as topical application (1.5 mg
propranolol) was intravenously administered to rabbits for
comparison. After intravenous injection, the periocular fat
showed the highest drug concentration among the periocular
tissues studied (Fig. 3). This trend was also observed after
oral administration (Fig. 2) and is likely attributable to the
high lipophilicity of propranolol [log Koct (octanol/water
partition coefficient) = 3.5]. Another notable observation was
that drug concentration in the plasma after intravenous injection was significantly higher than after topical application.
These results suggest that intravenous injection was less effective than topical application in delivering the drug to the
target periocular tissues but produced higher peak plasma
concentration, which may increase the likelihood of systemic
side effects.

Clinical implications
Although oral propranolol is considered a safe and welltolerated medication even in children,19 systemic side effects
of propranolol in the treatment of CHs have been reported,
and careful monitoring of patients with CHs during propranolol therapy is generally required.13 The results in Fig. 1
show that topical application of 1.5 mg propranolol could
produce and sustain relatively high concentrations of propranolol in the periocular tissues in the animal model. Particularly, drug concentrations in the 0.4 - 90 mg/g range were
observed in eyelids and extraocular muscles, tissues in which
or tissues adjacent to areas where CHs often grow. Although
the molecular mechanisms of propranolol and the therapeutic concentrations of propranolol in the treatment of CHs
are not known, the half maximal inhibitory concentration
(IC50) for propranolol in inhibiting tubulogenesis in a cell
culture model has been reported.22 Considering the IC50 of
*1.7 mM (0.4 mg/g), therapeutic concentrations of propranolol could be achieved in the target periocular tissues following topical delivery. The results in the present study
suggest that topical propranolol could be a promising
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alternative to oral propranolol in the treatment of periocular
CHs. Topically instilled propranolol could distribute into
the target tissues of the eye at pharmacologically active
concentrations with lower systemic exposure. Side effects
caused by systemic long-term administration of propranolol
in the treatment of periocular CHs might be avoided by
topical instillation. To our knowledge, this is the first systematic study of periocular tissue distribution of propranolol. It should be noted that the effectiveness of topical
delivery needs to be further investigated in human clinical
study, as propranolol distribution in humans can be different from that in animals and propranolol distribution to CH
tissues may be different from that to normal tissues. In addition, propranolol-associated cytotoxicity to the ocular tissues has been observed in cell culture models.23 Although
the concentrations of propranolol in the periocular tissues in
the present study were below the level considered to be
toxic using the average half maximal inhibitory concentration of 0.4 mM (103 mg/g) determined in cell proliferation
assay,23 local toxicity of ophthalmic propranolol needs to be
further investigated.

Conclusions
Distribution of propranolol in periocular tissues including eyelids and extraocular muscles has been studied and
compared after topical, intravenous, and oral administration. The feasibility of topical delivery of propranolol to the
periocular tissues has been demonstrated. Topical instillation
produced higher concentrations of the drug in the periocular
tissues and lower concentration of the drug in plasma as
compared with intravenous injection of the same dose of
1.5 mg propranolol. The drug concentrations in the eyelids
and extraocular muscles were generally maintained at higher
than 0.4 mg/g for 24 h after the topical application in the
present study. Conversely, oral administration of a clinically
relevant dose of 5 mg propranolol produced peak concentrations in the target periocular tissues of at least an order of
magnitude lower than those after topical application of
1.5 mg propranolol. Topical delivery of propranolol can provide higher drug concentrations in local periocular tissues
than oral and intravenous administration and, thus, may increase therapeutic efficacy in the treatment of periocular CHs.
Topical propranolol could be a promising alternative to oral
propranolol in the treatment of periocular CHs.
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